Johnson & Johnson Vaccine Demonstrates Durable Protection Against COVID-19 breakthrough infection

0 30

The Johnson & Johnson COVID-19 Vaccine Provides Long-Term Protection Against Breakthrough Infection, Hospitalization, and Intensive Care Unit Admission in the United States, according to real-world evidence.

Johnson & Johnson released new findings on Thursday from the largest study of its kind in the United States on the durability of COVID-19 vaccines, revealing that a single dose of the Johnson & Johnson COVID-19 vaccine provided long-term protection for up to six months against COVID-19 breakthrough infections, hospitalizations, and ICU admissions. The research was funded by Johnson & Johnson’s Janssen Pharmaceutical Companies and carried out in collaboration with the Department of Science-Aetion, Inc. and the Division of Pharmacoepidemiology at Brigham and Women’s Hospital and Harvard Medical School.

“We continue to undertake extensive efforts to study the durability of protection offered by the Johnson & Johnson vaccine amidst the ever-changing COVID-19 pandemic. While these are rapidly evolving data, we are seeing vaccine effectiveness against COVID-19-related hospitalization of approximately 80 percent from a single shot of the Johnson & Johnson vaccine, and this level of protection holds steady across the length of time studied thus far – up to six months. The robust and sustained durability of our COVID-19 vaccine reflects its unique underlying immunology. We previously reported that our vaccine induces a strong antibody response as well as an especially strong increase in T-cells that are consistent across variants, including Omicron,”

said Mathai Mammen, M.D., Ph.D., Executive Vice President, Pharmaceuticals, Janssen Research & Development LLC, Johnson & Johnson. 

Using the same methods, the latest study published on medRxiv looked at the durability profiles for all three vaccinations authorized or licensed in the United States across three outcomes of interest: COVID-19 infections, hospitalizations, and ICU admissions are all on the rise.

The study found that the Johnson & Johnson COVID-19 vaccine’s effectiveness in preventing breakthrough infections and hospitalizations was long-lasting. For hospitalizations and breakthrough infections, the mRNA vaccines (two doses) exhibited diminishing effectiveness. At no stage did any of the three vaccines exhibit signs of diminishing protection against COVID-19-related ICU admissions, indicating significant long-term protection against critically severe disease. The study was not intended to compare vaccination durability.

Leave A Reply

Your email address will not be published.